Last ¥4,443 JPY
Change Today +59.50 / 1.36%
Volume 1.5M
As of 2:00 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

eisai co ltd (4523) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/19/14 - ¥4,452
52 Week Low
02/6/14 - ¥3,694
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for EISAI CO LTD (4523)

Related News

No related news articles were found.

eisai co ltd (4523) Related Businessweek News

No Related Businessweek News Found

eisai co ltd (4523) Details

Eisai Co., Ltd. manufactures and sells pharmaceutical products worldwide. The company offers oncology-related products, such as Halaven, an anticancer agent; Aloxi, an antiemetic agent; Dacogen, a DNA methylation inhibitor; and Fragmin, an injectable anticlotting agent, as well as Symbenda/Treakisym, a treatment for low-grade non-Hodgkin's lymphoma and other types of lymphatic cancer. It also provides Aricept, an anti-Alzheimer's agent; Pariet/AcipHex, a proton-pump inhibitor; and Humira, a human anti-TNF-a monoclonal antibody. In addition, the company offers epilepsy products comprising Zonegran, Zebinix, and Fycompa, which are antiepileptic agents; and Inovelon/BANZEL for the treatment of Lennox-Gastaut syndrome. Further, it provides Methycobal, a peripheral neuropathy treatment; Warfarin, an oral anticoagulant; Actonel, an osteoporosis treatment; Selbex for the treatment of gastritis/gastric ulcer; consumer healthcare (over-the-counter) products, which include vitamin B2 preparation Chocola BB Plus; BELVIQ, an antiobesity agent; and Stronger Neo-Minophagen C/Glycyron tablets for liver disease/allergic disease treatment. Additionally, the company is involved in the research and development of various products under the areas of oncology and supportive care, vascular and immunological reaction, gastrointestinal and hepatic disorders, and neurology. It has collaboration agreement with Biogen Idec to develop and commercialize Alzheimer's disease treatments. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.

10,419 Employees
Last Reported Date: 06/20/14
Founded in 1941

eisai co ltd (4523) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

eisai co ltd (4523) Key Developments

Eisai Co., Ltd Enters a Joint Research Agreements to Develop New Antimalarial Medicines in Collaboration with Broad Institute

Eisai Co., Ltd. announced that it has entered into a joint research agreements for the development of new antimalarial medicines. The agreement is a joint development program with the Broad Institute, a collaborative research facility which involves researchers from Harvard University and the Massachusetts Institute of Technology. Eisai and Broad will work together on the optimization of compounds screened from Broad's library. These compounds are believed to be unique as they have a mechanism of action inhibiting protein synthesis, which is completely different to other existing antimalarial medicines. The goal is to identify those with the potential to be effective as new antimalarial medicines.

Eisai Co., Ltd and Kyorin Pharmaceutical Co., Ltd Enters into Agreement Concerning Compound Library Use for the Development of New Antibacterial Agents

Eisai Co., Ltd. and Kyorin Pharmaceutical Co., Ltd. announced that they have entered into an agreement concerning the evaluation and use of Eisai's compound library, which includes natural products, by Kyorin with the aim of leveraging both companies' resources for the discovery of innovative new antibacterial agents. Under this agreement, Eisai grants Kyorin the rights to evaluate the feasibility of developing compounds for the antibacterial field using the compound library owned by Eisai, and Eisai receives a certain lump-sum payment from Kyorin. In addition, in case that a license agreement is concluded in the future based on the terms of this agreement, Kyorin will receive the exclusive rights to research, develop, manufacture and market a compound as an antibacterial agent in Japan, and as a result, Kyorin will be in a position to expect to enhance its research and development pipeline.

Eisai Co., Ltd. Sells US Rights to Antiepileptic Treatment Zonegran to Concordia

Eisai announced that its US subsidiary has agreed to sell the US and Puerto Rican commercialisation rights for the antiepileptic treatment Zonegran (zonisamide) to Concordia Pharmaceuticals. Eisai will continue to hold the exclusive rights to Zonegran, which was originally created by Dainippon Pharmaceutical (now Sumitomo Dainippon Pharma), in Europe, North America, and Asia. Eisai has also agreed to act as Concordia's supplier of Zonegran to the US and Puerto Rican markets. Under the agreement, Eisai will retain rights to Zonegran outside the United States and Puerto Rico.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4523:JP ¥4,443.00 JPY +59.50

4523 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almirall SA €11.42 EUR -0.10
Cubist Pharmaceuticals Inc $66.55 USD -0.55
Salix Pharmaceuticals Ltd $164.23 USD +4.46
Synergy Health PLC 1,530 GBp +17.00
Theravance Inc $18.72 USD +0.09
View Industry Companies

Industry Analysis


Industry Average

Valuation 4523 Industry Range
Price/Earnings 40.3x
Price/Sales 2.0x
Price/Book 2.3x
Price/Cash Flow 41.9x
TEV/Sales 1.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EISAI CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at